DRUG IDENTIFICATION
Compositions
Fluticasone Propionate..250mcg
Salmeterol Xinafoate…36,8 mcg
Quantity corresponding to Salmeterol .. 25mcg
Excipients: Oleic Acid, anhydrous Ethanol, propellant gas norflurane (tetrafluoroethane or HFA 134a) s.q.f. one dose.
This product does not contain the CFC (harmful substance for the ozone layer).
Pharmaceutical form and contents
Suspension for inhalation in pressurized canister.
Canister of 120 doses.
Pharmacological therapeutic class:
Cyvax® is a bronchodilator – anti-asthmatic, associating two active substances:
Salmeterol Xinafoate: beta-2 mimetic bronchodilator of long duration of action.
Fluticasone Propionate:anti-inflammatory steroidal. (R: Respiratory system)
WHEN TO USE CYVAX® 250 mcg/25 mcg?
This drug is recommended for the continuous asthma treatment, in the following situations:
– Patients not adequately controlled by inhaled corticosteroids and taking an inhaled beta-2 mimetic bronchodilator short-acting “on demand”.
-Patients controlled by the administration of inhaled corticosteroid combined with continuous treatment with inhaled beta-2 mimetic long-acting.